White House withdraws nomination of Heidi Overton to lead FDA
The White House pulled Dr. Heidi Overton's nomination to lead the FDA following bipartisan resistance in the Senate regarding vaccines and vaping.
The White House pulled the nomination of Dr. Heidi Overton to lead the Food and Drug Administration on Tuesday, abandoning her bid amid growing indications that she lacked the votes needed to survive a crucial Senate committee test. Overton, a physician and White House domestic policy adviser, was nominated in August to bring a stabilizing Trump loyalist to an agency left leaderless after the tumultuous departure of Dr. Marty Makary. That promise of steady leadership collided with intense bipartisan resistance on Capitol Hill, where lawmakers questioned her scientific independence, her stance on childhood vaccines, and her execution of administration vaping policies.
Republican Sen. Bill Cassidy of Louisiana, who chairs the health committee, had previously called Overton's support for breaking up combination vaccines like the measles, mumps, and rubella shot almost disqualifying.
Cassidy remained undecided ahead of a vote scheduled for Wednesday, telling CBS News late Tuesday that a possible pathway to advance the nomination was still being discussed and that the committee had not formally told the White House it lacked the votes. Two sources familiar with the matter countered that the White House shared its decision to withdraw Tuesday evening while whip efforts were still underway.
Why Did Republican Support Collapse So Fast?
Beyond vaccines, Overton faced skepticism from Maine Republican Sen. Susan Collins over her approach to flavored e-cigarettes after the agency authorized the first fruit-flavored vaping products for adult smokers. Lawmakers also scrutinized her testimony regarding the FDA-approved abortion drug mifepristone. That friction compounded pressure from the Make America Healthy Again movement, whose allies blamed Overton for sidelining top health goals pursued by Health Secretary Robert F. Kennedy Jr.
Calley Means told Joe Rogan earlier this month that White House aides including Overton worked to advance a Supreme Court decision blocking thousands of lawsuits over the weedkiller glyphosate at the behest of industry lobbyists. There is a very concentrated group in the Trump administration that are antagonistic to what people voted for,
Means said on the program.
That outside conservative pushback mirrored troubles faced by other administration health picks. Trump’s first nominee for the Centers for Disease Control and Prevention, Dr. David Weldon, was replaced over doubts about his confirmation support, while two surgeon general nominees including Dr. Casey Means were also pulled.
What Does This Mean for the FDA Right Now?
The FDA regulates products accounting for about 20% of U.S. consumer spending, yet it has operated without a Senate-confirmed leader for months following the exit of Makary. The agency under Makary suffered from scientific disputes, leadership turnover, and low morale that saw about 20% of employees leave through layoffs, buyouts, retirements, or resignations.
Kyle Diamantas, an attorney and friend of Donald Trump Jr., currently runs the agency on an acting basis after previously serving as its top food official. With Republicans racing to confirm nominees before Democrats take control of the Senate in January, the White House had already begun interviewing alternative candidates on Tuesday, including potential acting chiefs who would bypass confirmation entirely. Two sources indicated that outgoing Kansas Republican Sen. Roger Marshall, a doctor who lost his reelection bid to Democrat Adam Hamilton earlier this month, is making a play for the post.
Cassidy defended the logic of installing a permanent commissioner despite policy disagreements, telling Face the Nation with Margaret Brennan on Sunday that we're not going to have perfection.
The question is, do we want a series of short-term administrators who probably will have more influence from the secretary, as opposed to someone who may be not, you know, the perfect candidate in somebody's mind, but at least would be a permanent one and have the ability to establish some independence?
Sen. Bill Cassidy, via CBS News
Cassidy faced little personal political downside in opposing nominees as his term winds down, having lost his primary race in June. Yet his ultimate pattern of voting for previous committee nominees left the exact threshold of resistance unpredictable until the White House pulled the plug.
Who Gains and Who Loses in the Senate Countdown?
The collapse of Overton's nomination hands a victory to Senate Democrats and health advocates who demanded stricter adherence to established scientific standards on vaccines and consumer safety. At the same time, it deals a setback to allies of former White House chief of staff Susie Wiles, who departed her role earlier this month and was seen as close to Overton.
With only a matter of weeks left in the current congressional term, the administration must decide whether to gamble on another Senate confirmation fight or leave the agency under acting leadership. Will the White House put forward a new permanent nominee before January, or will the FDA finish out the term under temporary chiefs?